GlassScriptPhysician profile
Neil T Shmunes
NPI 1518068329
$1,790.87
in general payments reported to CMS, 2019-2025
19 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $114 · 2021: $115 · 2022: $405 · 2023: $506 · 2024: $74.43 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $429.07 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $337.91 | 2019-2021 | |
| Alcon Vision LLC | $179.05 | 2019-2025 | Argos |
| Sight Sciences, INC. | $178.39 | 2023 | Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $140.62 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $128.20 | 2022-2025 | Vyzulta |
| Glaukos Corporation | $95.29 | 2021-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $69.26 | 2022-2023 | Tepezza |
| Amgen INC. | $53.04 | 2024-2025 | Tepezza |
| Allergan, INC. | $36.09 | 2021-2022 | |
| Oyster Point Pharma, INC. | $20.20 | 2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $19.99 | 2024 | |
| Eyepoint US, INC. | $18.12 | 2021 | |
| Ocular Therapeutix, INC. | $16.64 | 2023 | Dextenza |
| Novartis Pharmaceuticals Corporation | $16.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $14.49 | 2023 | Baerveldt Glaucoma Implant (250) |
| Shire North American Group INC | $13.66 | 2019 | |
| Aerie Pharmaceuticals, INC. | $12.61 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Shmunes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.